<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04454580</url>
  </required_header>
  <id_info>
    <org_study_id>HMA-V</org_study_id>
    <nct_id>NCT04454580</nct_id>
  </id_info>
  <brief_title>Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy</brief_title>
  <official_title>Retrospective, Observational, Monocentric Study to Assess Efficacy and Safety of the Combination of an Hypomethylating Agent in Combination With Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Maggiore Di Trieste</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Maggiore Di Trieste</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, observational, monocentric study to evaluate the efficacy and safety
      of the combination of an hypomethylating agent with venetoclax newly diagnosed patients with
      acute myeloid leukemia ineligible for intensive chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis of acute myeloid leukemia (AML) patients who are ineligible for intensive
      chemotherapy is poor (Kantarjian et al). Hypomethylating agents, azacitidine and decitabine,
      are effective and less toxic regimens, and treatment with these agents has improved the
      prognosis of these patients (Fenaux et al).

      Venetoclax, a Bcl-2 inhibitor, in combination with azacitidine has shown efficacy in AML
      patients with complete remission rate of 73% and overall survival at 2 years of 40-50% (Di
      Nardo et al).

      On these grounds, the aim of this study is to collect the real-life experience with this
      combination in previously untreated AML patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 26, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>every three months after started treatment up to two years</time_frame>
    <description>according to European Leukemia Network (ELN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>every three months after started treatment up to two years</time_frame>
    <description>according to European Leukemia Network (ELN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphologic leukemia-free state (MLFS)</measure>
    <time_frame>every three months after started treatment up to two years</time_frame>
    <description>according to European Leukemia Network (ELN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>from the start of the treatment until the date of documented progression or date of death from any cause, assessed up to 2 years</time_frame>
    <description>from start of the treatment to progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from the start of the treatment until the date of documented progression or date of death from any cause, assessed up to 2 years</time_frame>
    <description>from start of the treatment to progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events and serious adverse events</measure>
    <time_frame>through study completion, for an average of 1 year</time_frame>
    <description>according to CTCAE v. 4.0</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Myeloid Leukemia, Adult</condition>
  <condition>Hypomethylating Agents</condition>
  <condition>Venetoclax</condition>
  <arm_group>
    <arm_group_label>treated patients</arm_group_label>
    <description>hypomethylating agent (azacitidine or decitabine) in combination with venetoclax</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>treatment with azacitidine or decitabine in combination with venetoclax</description>
    <arm_group_label>treated patients</arm_group_label>
    <other_name>Azacitidine</other_name>
    <other_name>Decitabine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes adult patients with newly diagnosed acute myeloid leukemia
        not eligible for intensive chemotherapy, treated in a referral center for hematology
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥18 years

          -  newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy

        Exclusion Criteria:

          -  promyelocytic acute myeloid leukemia

          -  patients who have already received one or more prior lines of therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Francesco Zaja, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>SC Ematologia Ospedale Maggiore Trieste</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Zaja, Professor</last_name>
    <phone>+390403992888</phone>
    <email>francesco.zaja@asugi.sanita.fvg.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>SC Ematologia Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zaja, Professor</last_name>
      <phone>+390403992888</phone>
      <email>francesco.zaja@asugi.sanita.fvg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21.</citation>
    <PMID>20026804</PMID>
  </reference>
  <reference>
    <citation>DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.</citation>
    <PMID>30361262</PMID>
  </reference>
  <results_reference>
    <citation>Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.</citation>
    <PMID>27895058</PMID>
  </results_reference>
  <results_reference>
    <citation>Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25;116(22):4422-9. doi: 10.1182/blood-2010-03-276485. Epub 2010 Jul 28.</citation>
    <PMID>20668231</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>June 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Maggiore Di Trieste</investigator_affiliation>
    <investigator_full_name>Francesco Zaja</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

